Gene editing may provide hope for the treatment of Fragile X, the leading genetic cause of autism.
Fragile X syndrome patients with prematuration had a much earlier onset of neurological problems, including earlier symptoms of neurodegeneration. They also experienced emotional processing problems. Some of the most common emotional processing disorders reported were mood regulation, anxiety, and psychosis.
Researchers report functional alterations in L-type calcium channels were detected in models of Fragile X syndrome.
Researchers have successfully reduced some symptoms associated with fragile X syndrome in mice with the help of CRISPR-Cas 9 gene editing.
According to researchers, a drug approved by the FDA may reverse some of the symptoms associated with Fragile X syndrome. The drug can reverse hyper-excitability that leads to sensory hypersensitivity.
A new neuroimaging study reveals babies with Fragile X syndrome have less developed white matter in the brain compared to children without the condition.
Researchers report neurons in mice with a genetic defect that causes Fragile X are similar to those in mice without the syndrome, but fail to interact correctly. This failure results in the cognitive impairment associated with FXS.
According to researchers, treatment that target chromatin remodelers may provide new avenues of treatment for Fragile X Syndrome and other autism spectrum disorders.
A new study reports children with Fragile X syndrome show bias toward threatening rather than positive emotion.
According to researchers, people with Fragile X have 'noisier' brains, which can impair information flow and make social interactions more difficult.
A new study looks at some of the underlying causes of fragile X syndrome and offers suggestions for new treatment targets.
A new study links enzyme MMP-9 to autistic behaviors associated with Fragile X.
